Edgewise Therapeutics Announces 12-Month Topline Results From The ARCH Open Label Study Of EDG-5506 In Adults With Becker Muscular Dystrophy
Portfolio Pulse from Happy Mohamed
Edgewise Therapeutics announces positive 12-month topline results from the ARCH study of EDG-5506 in adults with Becker Muscular Dystrophy (BMD). The study showed a sustained positive trend in NSAA scores and significant decreases in muscle damage biomarkers. The company is continuing to enroll patients in the CANYON Phase 2 trial, which now includes a pivotal cohort called GRAND CANYON.
June 26, 2023 | 8:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Edgewise Therapeutics' positive 12-month results from the ARCH study of EDG-5506 in BMD patients may boost investor confidence in the company's ongoing CANYON Phase 2 trial.
The positive 12-month results from the ARCH study indicate that EDG-5506 has potential in treating BMD patients. This may lead to increased investor confidence in the company's ongoing CANYON Phase 2 trial, which now includes a pivotal cohort called GRAND CANYON. As a result, the stock price of Edgewise Therapeutics (EWTX) is likely to go up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100